Siga Monkeypox Antiviral to Undergo First Human Tests in UK (1)

Siga Technologies Inc.’s antiviral Tpoxx, which has mainly been shown to fight monkeypox in animal studies, will undergo human testing by University of Oxford researchers as countries look for ways to tackle a growing outbreak with limited vaccine supply.

The study will enroll at least 500 people across the UK who will take either take the antiviral or a placebo twice a day for two weeks at home, according to the team of scientists leading the trial. The UK trial is a world first in testing the efficacy of an antiviral in monkeypox patients, said the researchers who previously led ...